Evidence map›Paper›PMID 33889299›Full record

ArticleOncotarget2021

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Yehia I Mohamed, Sunyoung Lee, Lianchun Xiao, Manal M Hassan, Aliya Qayyum, Rikita Hiatia, Roberto Carmagnani Pestana, Abedul Haque, Bhawana George, Asif Rashid and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yehia I MohamedDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sunyoung LeeDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lianchun XiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manal M HassanDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aliya QayyumDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rikita HiatiaDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roberto Carmagnani PestanaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abedul HaqueDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bhawana GeorgeDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Asif RashidDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dan G DudaSteele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Hesham ElghazalyDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey S MorrisDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James YaoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hesham M AminDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Bayesian Network-Based Integrative Genomics Methods for Precision MedicineR01CA244845 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BALADANDAYUTHAPANI, VEERABHADRAN, MORRIS, JEFFREY S · 2021 to 2024
$1.8M
NCI NIH HHS R01 CA244845
6 · The paper itself

Abstract

backgroundSorafenib was the first systemic therapy approved for the treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival and treatment outcomes and guide HCC systemic therapy. Type 1 insulin-like growth factor (IGF-1)/CTP composite score has emerged as a potential hepatic reserve assessment tool. Our study investigated the association of the IGF/CTP score with overall survival (OS) and progression-free survival (PFS) of HCC patients treated with sorafenib. MATERIALS AND

methodsIn this prospective study, patients with HCC were treated with sorafenib and followed up until progression/death. We calculated the IGF/CTP score and used the Kaplan-Meier method and log-rank test to estimate and compare the time-to-event outcomes between patient subgroups.

results171 patients were included, 116 of whom were CTP class A. Median PFS for IGF/CTP score AA and AB patients were 6.88 and 4.28 months, respectively (

conclusionsIn CTP class A patients, IGF/CTP score B was associated with shorter PFS and OS, however, study was underpowered to reach statistical significance. If validated in larger cohorts, IGF/CTP score may serve as stratification tool in clinical trials, a hepatic reserve assessment tool for HCC outcomes prediction and to assist in therapy decisions.

Indexed as

Child-Pughhepatocellular carcinomaIGF-1liver reservesorafenib

Identifiers

PMID33889299
PMCPMC8057275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.